Vanguard Group
DNA icon

Vanguard Group’s Ginkgo Bioworks DNA Stock Holding History

Vanguard Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$24.1M Buy
2,900,952
+420,448
+17% +$4.53M ﹤0.01% 2538
2025
Q3 		$36.2M Buy
2,480,504
+99,379
+4% +$1.19M ﹤0.01% 2314
2025
Q2 		$26.8M Buy
2,381,125
+250,118
+12% +$1.94M ﹤0.01% 2417
2025
Q1 		$12.1M Buy
2,131,007
+117,449
+6% +$1.2M ﹤0.01% 2742
2024
Q4 		$19.8M Sell
2,013,558
-592,205
-23% -$5.08M ﹤0.01% 2588
2024
Q3 		$21.2M Sell
2,605,763
-868,338
-25% -$8.7M ﹤0.01% 2567
2024
Q2 		$46.5M Buy
3,474,101
+327,684
+10% +$9.78M ﹤0.01% 2179
2024
Q1 		$146M Sell
3,146,417
-173,085
-5% -$8.96M ﹤0.01% 1673
2023
Q4 		$224M Buy
3,319,502
+11,577
+0.3% +$709K ﹤0.01% 1437
2023
Q3 		$239M Buy
3,307,925
+100,406
+3% +$8.03M 0.01% 1338
2023
Q2 		$239M Buy
3,207,519
+435,236
+16% +$25.8M 0.01% 1377
2023
Q1 		$147M Buy
2,772,283
+234,251
+9% +$14.8M ﹤0.01% 1619
2022
Q4 		$172M Buy
2,538,032
+391,156
+18% +$36M ﹤0.01% 1512
2022
Q3 		$268M Sell
2,146,876
-21,500
-1% -$2.56M 0.01% 1205
2022
Q2 		$206M Buy
2,168,376
+1,435,041
+196% +$175M 0.01% 1404
2022
Q1 		$118M Sell
733,335
-5,318
-0.7% -$1.04M ﹤0.01% 1849
2021
Q4 		$246M Buy
+738,653
New +$351M 0.01% 1474

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group's DNA Position: Q4 2025 in Review

Vanguard Group increased its Ginkgo Bioworks (DNA) stake by 17% in Q4 2025, buying an estimated $4.53M and bringing the position to 2,900,952 shares worth $24.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2538.

Vanguard Group first reported a position in DNA in Q4 2021 and has held it in 17 quarters since. The position peaked at $268M in Q3 2022. 180 funds tracked by Wall St. Rank hold DNA as of Q4 2025.

  • Vanguard Group held 2,900,952 shares of Ginkgo Bioworks worth $24.1M as of Q4 2025.
  • Vanguard Group bought 420,448 Ginkgo Bioworks shares in Q4 2025, an estimated $4.53M.
  • Ginkgo Bioworks made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2538 holding.
  • Vanguard Group first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 17 quarters since.
  • Vanguard Group's Ginkgo Bioworks position peaked at $268M in Q3 2022.
  • 180 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.